Get the Stockscreener App
47.99
2.75%
1.29
Soleno Therapeutics Inc stock is traded at $47.99, with a volume of 243.82K.
It is up +2.75% in the last 24 hours and down -6.52% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$46.70
Open:
$46.82
24h Volume:
243.82K
Relative Volume:
0.49
Market Cap:
$2.14B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-16.01
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+6.77%
1M Performance:
-6.52%
6M Performance:
-9.19%
1Y Performance:
+9.10%
1-Day Range:
$46.11
$48.49
1-Week Range:
$43.00
$48.49
52-Week Range:
$36.61
$60.92
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
48.06 | 2.14B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.76 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.32 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.12 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.63 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
When (SLNO) Moves Investors should Listen - Stock Traders Daily
Stifel maintains Buy on Soleno Therapeutics, $74 target - Investing.com
Is Soleno Therapeutics Inc (NASDAQ: SLNO) A Good Pick For New Investors Now? - Stocks Register
FY2025 EPS Estimates for SLNO Reduced by Cantor Fitzgerald - Defense World
Stifel Nicolaus Initiates Coverage on Soleno Therapeutics (NASDAQ:SLNO) - Defense World
Equities Analysts Offer Predictions for SLNO Q1 Earnings - Defense World
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Stifel resumes Soleno coverage with 'buy' rating, citing potential of rare disease drug - TradingView
Stifel resumes Soleno Therapeutics with Buy, sets $74 target - Investing.com
New York State Common Retirement Fund Has $347,000 Holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Rhumbline Advisers Acquires 3,624 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
Soleno Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cantor Fitzgerald maintains $67 target on Soleno Therapeutics stock By Investing.com - Investing.com Canada
Soleno Therapeutics’ (SLNO) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Exploring US High Growth Tech Stocks In March 2025 - Simply Wall St
Cantor Fitzgerald maintains $67 target on Soleno Therapeutics stock - Investing.com India
(SLNO) Trading Signals - Stock Traders Daily
Soleno Therapeutics Reports 2024 Financial Results and Strategic Progress - MSN
Soleno Therapeutics (NASDAQ:SLNO) Releases Earnings Results, Misses Estimates By $0.41 EPS - MarketBeat
Soleno Therapeutics (SLNO) to Release Quarterly Earnings on Wednesday - MarketBeat
SOLENO THERAPEUTICS INC SEC 10-K Report - TradingView
Soleno Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - TradingView
Can Soleno's $318M War Chest Power DCCR Through FDA Priority Review for Rare Disease Treatment? - StockTitan
Major Public Health Interest? Scholar, Insmed & Soleno Ask EMA To Fast-Track Their Products - Pink Sheet
Allspring Global Investments Holdings LLC Trims Stock Position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Allspring Global Investments Holdings LLC Sells 13,396 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) - Defense World
TimesSquare Capital Management LLC Makes New Investment in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
(SLNO) Long Term Investment Analysis - Stock Traders Daily
Soleno Therapeutics (NASDAQ:SLNO) Stock Passes Above Fifty Day Moving Average – Should You Sell? - Defense World
Soleno Therapeutics (NASDAQ:SLNO) Stock Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Brokerages Set Soleno Therapeutics, Inc. (NASDAQ:SLNO) Price Target at $71.20 - Defense World
What is Lifesci Capital's Estimate for SLNO Q4 Earnings? - MarketBeat
Soleno Therapeutics (NASDAQ:SLNO) Upgraded by Lifesci Capital to Strong-Buy Rating - MarketBeat
Trend Tracker for (SLNO) - Stock Traders Daily
Equities Analysts Set Expectations for SLNO Q4 Earnings - Defense World
SLNO Stock Sees Surge of Approximately 3.38% in Last Five Days - Knox Daily
What was Soleno Therapeutics Inc (SLNO)’s performance in the last session? - US Post News
Lifesci Capital Upgrades Soleno Therapeutics (NASDAQ:SLNO) to “Strong-Buy” - Defense World
BlackRock, Inc. Reduces Stake in Soleno Therapeutics Inc - GuruFocus.com
Moody Aldrich Partners LLC Purchases New Shares in Soleno Therapeutics, Inc. (NASDAQ:SLNO) - MarketBeat
Soleno Therapeutics to Participate in Upcoming February Investor Conferences - The Manila Times
Soleno Therapeutics, Inc. to Participate in February Investor Conferences - Nasdaq
Rare Disease Pioneer Soleno Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Soleno Therapeutics Inc Stock (SLNO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Yen Kristen | SEE REMARKS |
Jan 03 '25 |
Sale |
46.18 |
2,340 |
108,053 |
76,605 |
| Mackaness James H | CHIEF FINANCIAL OFFICER |
Jan 02 '25 |
Sale |
45.41 |
4,083 |
185,406 |
115,089 |
| Mackaness James H | CHIEF FINANCIAL OFFICER |
Jan 03 '25 |
Sale |
46.18 |
3,791 |
175,055 |
111,298 |
| Hirano Patricia C | SEE REMARKS |
Jan 02 '25 |
Sale |
45.41 |
1,571 |
71,338 |
107,361 |
| Hirano Patricia C | SEE REMARKS |
Jan 03 '25 |
Sale |
46.18 |
1,459 |
67,371 |
105,902 |
| Anish Bhatnagar | CHIEF EXECUTIVE OFFICER |
Jan 02 '25 |
Sale |
45.41 |
10,937 |
496,640 |
708,616 |
| Anish Bhatnagar | CHIEF EXECUTIVE OFFICER |
Jan 03 '25 |
Sale |
46.18 |
10,154 |
468,875 |
698,462 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):